<?xml version="1.0" encoding="UTF-8"?>
<ref id="B59">
 <label>59.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zhu</surname>
    <given-names>FC</given-names>
   </name>
   <name>
    <surname>Hou</surname>
    <given-names>LH</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>JX</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>SP</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>GR</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial</article-title>. 
  <source>Lancet</source> (
  <year>2015</year>) 
  <volume>385</volume>:
  <fpage>2272</fpage>â€“
  <lpage>9</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60553-0</pub-id>
  <?supplied-pmid 25817373?>
  <pub-id pub-id-type="pmid">25817373</pub-id>
 </mixed-citation>
</ref>
